Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2025-05-05 00:00:00 ET · period of report 2025-05-01 · accession 0001415889-25-011992 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-05-05 | 2025-05-02+ | KNSA | Moat Ross | Chief COMMERCIAL Off | M - OptEx | $17.76 | +10.1K | 15.7K | +182% | +$179.8K |
| DM | 2025-05-05 | 2025-05-02+ | KNSA | Moat Ross | Chief COMMERCIAL Off | S - Sale+OE | $28.00 | -10.1K | 9,415 | -52% | -$283.4K |
| DM | 2025-05-05 | 2025-05-01 | KNSA | Moat Ross | Chief COMMERCIAL Off | A - Grant | $0.00 | +26.5K | 8,303 | New | $0 |
| DM | 2025-05-05 | 2025-05-02+ | KNSA | Moat Ross | Chief COMMERCIAL Off | M - OptEx | $0.00 | -10.1K | 27.4K | -27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2025-05-02 | M | A | 3,850 | $17.76 | 13,265 | D | — | — | |
| 2 | Common | Class A Ordinary Share | 2025-05-02 | S | D | 3,850 | $28.00 | 9,415 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 3 | Common | Class A Ordinary Share | 2025-05-05 | S | D | 6,272 | $28.00 | 9,415 | D | — | — | (F3) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.04. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 4 | Common | Class A Ordinary Share | 2025-05-05 | M | A | 6,272 | $17.76 | 15,687 | D | — | — | |
| 5 | Derivative | Performance Share Unit | 2025-05-01 | A | A | 4,976 | $0.00 | 4,976 | D | — · — to — | 4,976 Class A Ordinary Share | (F5) The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. (F4) Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. (F6) The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions. |
| 6 | Derivative | Performance Share Unit | 2025-05-01 | A | A | 5,225 | $0.00 | 5,225 | D | — · — to — | 5,225 Class A Ordinary Share | (F5) The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. (F4) Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. (F7) The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. |
| 7 | Derivative | Performance Share Option | 2025-05-01 | A | A | 8,043 | $0.00 | 8,043 | D | $27.74 · — to 2035-04-30 | 8,043 Class A Ordinary Share | (F5) The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. (F8) The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions. |
| 8 | Derivative | Performance Share Option | 2025-05-01 | A | A | 8,303 | $0.00 | 8,303 | D | $27.74 · — to 2035-04-30 | 8,303 Class A Ordinary Share | (F5) The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. (F9) The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. |
| 9 | Derivative | Share Option | 2025-05-02 | M | D | 3,850 | $0.00 | 33,661 | D | $17.76 · — to 2033-08-31 | 3,850 Class A Ordinary Share | (F10) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. |
| 10 | Derivative | Share Option | 2025-05-05 | M | D | 6,272 | $0.00 | 27,389 | D | $17.76 · — to 2033-08-31 | 6,272 Class A Ordinary Share | (F10) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. |